Introducing Ritedose— the Largest CDMO Specializing in Blow-Fill-Seal Technology in the US

Ritedose Blow-Fill-Seal Technology | Aerial view of Ritedose pharmaceutical manufacturing facilities in Columbia, South Carolina, showcasing the largest U.S. Blow-Fill-Seal CDMO.

This overview explores Ritedose, the largest U.S. pharmaceutical CDMO, and how its aseptic Blow-Fill-Seal technology supports large-scale branded and generic drug manufacturing.

Introducing Ritedose 

As we finish celebrating our 30th year, we thought we’d take a step back and re-introduce ourselves! Who is the Ritedose Corporation, what do we do, and how and why do we do it? 

Ritedose is the country’s largest pharmaceutical contract development and manufacturing company (CDMO) that specializes in aseptic Blow-Fill-Seal (BFS) technology. We use BFS to manufacture branded drugs for other pharmaceutical companies, as well as generic drugs that are no longer under patent protection. Ritedose has the capacity to produce more than 2.6 billion doses every year for a diverse customer base of startups, major pharmaceutical companies, wholesalers and retail pharmacies. 

The History and Growth of Ritedose Since 1995 

We started in 1995 with just 11 people in a 52,000-square-foot facility, making 42 million doses annually. Today, we employ over 600 people who work in facilities totaling more than 500,000 square feet capable of 2.6B+ doses a year. For the past 25 years, we’ve had a flawless track record of reliability, and since 2012, we have delivered more than 12 billion doses with no interruptions. We maintain this level of quality to ensure that patients always have access to safe and reliable medicine. After all, it’s the patients who are at the heart of everything we do. 

But it’s not just patients who drive our mission. We’ve also invested in our community, supporting local and national organizations through financial contributions and volunteer efforts. This year, we launched the 1,000 Hours of Purpose initiative, dedicating company time to serving the South Carolina Midlands community. We’re also considered an employer of choice in the Midlands, fostering a culture of excellence, purpose and professional growth.  

So, what makes Ritedose, Ritedose? 

Passion and Precision with a Purpose. What Ritedose Does as a CDMO 

Defining Contract Development and Manufacturing for Pharmaceuticals 

First, we’re a leading CDMO. Contract development and manufacturing starts with the earliest stages of clinical trials, supporting the process through New Drug Application filings with the U.S. Food and Drug Administration (FDA), to scaling up production, commercial manufacturing in our facilities, and ultimately, filling and finishing and distributing the drug to our customers and their patients. Our work can start at any point along this journey to drug delivery.  

Recently, we became the manufacturer of Verona Pharmaceuticals’ newly approved drug for chronic obstructive pulmonary disease, Ohtuvayre. The drug is the first new type of treatment for COPD in more than 20 years.  

Drug Development Support from Formulation to Fill and Finish 

As we are showcasing the largest U.S. Blow-Fill-Seal Technology, Our CDMO products include solutions, emulsions and suspensions for inhalation, ophthalmic, optic and oral drugs. Container types include standardized inhalation ampules, ear drops, eye drops and some unique patented designs.

Ritedose Generics and Approvals for High-Demand Medications 

Why Generics Matter for Patient Access and Affordability 

Ritedose Pharmaceuticals is also a leading generic drug supplier. Generics are medicines with the same active ingredient as brand-named drugs, but that no longer have the same patent protections. This allows other companies to make the products, leading to generics being less expensive than the branded counterparts, but they are manufactured under the same regulations and safety standards as branded drugs.  

Generic drugs play a vital role in making essential treatments more accessible, and at Ritedose, we never compromise on quality or safety to ensure patient care. With the largest portfolio of nebulized inhalation therapies available, we are uniquely positioned to serve wholesalers and retail pharmacy chains with reliable solutions—all under one roof.  

2025: Three New Generic Drugs and Expanding Our Portfolio 
  • We also received FDA approval for manufacturing and distributing generic Albuterol Sulfate Inhalation Solution, 0.5% (2.5 mg/0.5 mL)*, helping address a national shortage of the much-needed respiratory drug. *Potency expressed as albuterol, equivalent to 3 mg of albuterol sulfate 
  • And most recently, we received FDA approval to manufacture tobramycin inhalation solution, increasing our nebulized portfolio to be the largest in the nation, and adding our first cystic fibrosis (CF) product. 

Blow-Fill-Seal Technology at Ritedose 

Whether as a CDMO or generics powerhouse, Ritedose makes all of its products using Blow-Fill-Seal technology. In short, BFS is a closed system that forms, fills, and seals the products in a continuous manufacturing process:

  • Blow—the container is formed by blowing the parison (typically a low density polyethylene) into a mold, creating the container’s shape.  
  • Fill—then, the container is filled with the drug product. Each dose is delivered accurately through time/pressure filling. 
  • Seal—the container is then sealed as the top section of the molds come together.  

Industry Growth and Ritedose Recognition as a Blow-Fill-Seal Technology Leader 

BFS is taking the pharmaceutical world by storm. There has also been growing crossover into other industries with interests in aseptic processing, such as food and personal care products. It’s estimated that the BFS market, now in excess of $3.1 billion, will grow by 6.8% every year through 2033, when it’s estimated to total $7 billion.  

Ritedose is a leader in BFS, consistently ranking as one of the top five pharmaceutical companies in the world using this technology. In fact, we were chosen by the Pharmaceutical Blow-Fill-Seal International Operators Association (BFS-IOA), the global trade association for Blow-Fill-Seal Technology users, to hold its American meeting at Ritedose, in Columbia, SC for 2025.  

Expanding Capacity and Operational Excellence  

We have expanded our capacity for development and manufacturing, installing two additional high-speed BFS lines that add 360-million-unit doses for ophthalmic and respiratory medications.  

We’ve also added a seventh Syntegon packaging line, doubling our capacity to pack individually wrapped medications in vials. 

As the largest U.S. CDMO using BFS, we’ve had a 100% customer retention rate over 25 years and a flawless track record of reliability, delivering billions of doses since 2012 with no patient interruptions.  

Commitment to Quality and Compliance Standards 

Rite the First Time Quality Philosophy 

How can Ritedose do this? Our professionals use their expertise and dedication to make sure we always meet FDA and cGMP standards, with our “Rite the First Time” commitment to quality 

Compliance Success with FDA and National Pharmacy Boards 

In fact, Ritedose has an exceptional inspection and compliance history by the FDA, state boards of pharmacy, US Pharmacopeia, and the National Association of Boards of Pharmacy. We are also always working to minimize waste and delays and therefore, doubt. We are constantly improving our processes to consistently approach our goal for zero manufacturing errors.  

Quality Testing Methods in Chemistry, Microbiology, and Validation 

More than anything else, pharmaceutical companies are searching for the highest quality, and at Ritedose, we’re maintaining our track record by giving it our full attention. This means methods in wet chemistry, chromatography and instrument analysis to detect formulation imperfections and impurities; microbiology and real-time environmental monitoring to ensure sterility; validation methodology from spreadsheets, equipment, cleaning and sterility assurance; and quality assurance with integrated ERPs, e-documents, electronic batch records, supplier management and change management systems.  

How Ritedose Partners with Customers 

We also work closely with our customers. There’s no “one size fits all” concept here at Ritedose. For decades, we’ve helped customers achieve transformative growth and scale-up ambitions with tailored processes, from early phase clinical trials to commercialization. Our formulation capabilities include sterile filtration, bulk sterilization, potent compounds, oxygen- and temperature-sensitive products (from 160 to 3,600 liters in an ISO 8 classified area), and our average time from formulation to shipment for commercialized products is between 18 and 20 days. 

Who We Are—Beyond Manufacturing 

We always say that patients are at the heart of what we do. So, who are we? Our employees put their heart, soul and brainpower into getting safe drug delivery right the first time, every time. We foster a culture of excellence, purpose and professional growth for our current employees.  

And, we’re building a future workforce by partnering with colleges and universities across South Carolina, developing top industry talent.   

Our Commitment to Community Impact 

Our 1,000 Hours of Purpose initiative with the United Way of the Midlands donates 1,000 hours of employee time to support various local organizations addressing basic human needs like hunger and housing.  Employees receive monthly opportunities for a full day of volunteering with  local organizations such as Homeless No More, which supports people who are temporarily unhoused; Home Works of America, which provides home repair services to low-income homeowners; Palmetto Place, a safe shelter for homeless youth in South Carolina; and Transitions, which helps move previously unhoused people into new homes. Also, last year we marked $66,000 in fundraising for the American Heart Association’s Field Day events.  

And last but not at all least, we are donating one million doses of our products to the national charitable medication distributor, Dispensary of Hope, to provide respiratory medications to low-income and chronically ill patients nationwide. 

The Future of Ritedose in CDMO and BFS Innovation 

We hope this gives you a solid introduction to who we are and what we’re about at Ritedose! We go above and beyond for our customers, doing whatever it takes to meet and exceed their needs.  We help our customers achieve extraordinary results.  

Our team is the most experienced in our industry. We help customers see around corners, avoid problems before they start, and capture opportunities before the competition. We are proud of our decades-long relationship with our customers, and the new relationships we’re forging and will continue to forge! The BFS and CDMO industries have a bright future, and we look forward to working with you to be a part of it! 

 

Contact us today to see how we can partner with you. 

Frequently Asked Questions

What makes Blow-Fill-Seal technology a core part of Ritedose’s manufacturing capabilities?

Summary: Blow-Fill-Seal technology serves as the foundation of Ritedose’s sterile pharmaceutical manufacturing platform for branded and generic medications.

Full answer: Ritedose has built its manufacturing operations around Blow-Fill-Seal technology because it supports the efficient production of sterile liquid medications while maintaining high standards of quality and consistency. The process forms a plastic container, fills it with medication, and seals it automatically, helping reduce contamination and error risks. Once primarily used for respiratory and ophthalmic products, BFS is expanding into more complex formulations while supporting domestic manufacturing and reducing dependence on vulnerable global supply chains.

What pharmaceutical services does Ritedose provide as a CDMO?

Summary: Ritedose provides contract development and manufacturing services that support pharmaceutical products from formulation through commercial production.

Full answer: As a contract development and manufacturing organization, Ritedose helps pharmaceutical companies move products from development to commercial manufacturing. Its capabilities include formulation support, fill and finish operations, sterile manufacturing, process development, and large-scale commercial production using Blow-Fill-Seal technology. Ritedose can also support investigational new drug submissions, provide drugs for clinical trials through New Drug Application approval, and scale production for commercialization.

What types of drug formulations can be manufactured using Ritedose’s BFS platform?

Summary: Ritedose’s manufacturing platform supports sterile liquid formulations including solutions, suspensions, and emulsions.

Full answer: The Blow-Fill-Seal platform can accommodate a variety of sterile liquid drug formulations, including solutions, suspensions, and emulsions intended for respiratory, ophthalmic, oral, and other pharmaceutical applications. BFS is particularly well suited for products that require contamination control, reduced human intervention, single-use packaging, and consistent dose delivery. Ritedose has built a strong BFS platform in the United States with a particular focus on respiratory and ophthalmic drug delivery.

Why is manufacturing capacity important when selecting a pharmaceutical CDMO?

Summary: Manufacturing capacity helps ensure products can be supplied consistently as demand grows while helping prevent drug shortages.

Full answer: A pharmaceutical manufacturing partner should have the infrastructure needed to support current production requirements and future growth. Strong manufacturing capacity allows companies to scale production, respond to increased market demand, and help maintain a reliable medication supply throughout the product lifecycle. Ritedose specializes in aseptic Blow-Fill-Seal technology and uses BFS to manufacture branded drugs for pharmaceutical partners as well as generic medications. Its manufacturing platform has the capacity to produce more than 2.6 billion doses annually.

What pharmaceutical packaging formats are supported by Blow-Fill-Seal manufacturing?

Summary: Blow-Fill-Seal manufacturing supports sterile packaging formats including unit-dose ampules and ophthalmic containers.

Full answer: Blow-Fill-Seal technology can produce a variety of pharmaceutical container designs based on product requirements. These include inhalation ampules, eye drop containers, ear drop containers, and specialized proprietary packaging formats that support different therapeutic applications while maintaining sterility. Ritedose’s CDMO capabilities include solutions, emulsions, and suspensions for inhalation, ophthalmic, otic, and oral drug products.

Why do pharmaceutical companies partner with specialized CDMOs?

Summary: Specialized CDMOs provide technical expertise, manufacturing infrastructure, and production experience that help bring pharmaceutical products to market.

Full answer: Developing and manufacturing pharmaceutical products requires specialized facilities, regulatory expertise, and advanced production technologies. Working with an experienced CDMO gives pharmaceutical companies access to established manufacturing capabilities while allowing them to focus on product development. Ritedose provides tailored processes from early-phase clinical trials through commercialization, including sterile filtration, bulk sterilization, potent compounds, and oxygen- and temperature-sensitive products.

How does manufacturing experience support successful pharmaceutical commercialization?

Summary: Manufacturing experience supports an efficient transition from development to commercial production and provides resilience when events affect production.

Full answer: Commercial manufacturing requires careful planning, validated production processes, quality oversight, and operational expertise. Experienced manufacturers can help manage scale-up activities, support regulatory requirements, and establish reliable processes that prepare products for long-term commercial success. Ritedose professionals apply their expertise to meet FDA and cGMP standards while following the company’s Rite the First Time commitment to quality.

Why is industry leadership important in pharmaceutical manufacturing?

Summary: Industry leadership demonstrates a manufacturer’s experience, technical expertise, and commitment to continuous improvement.

Full answer: Industry-leading manufacturers invest in advanced technologies, workforce development, quality systems, and innovation. Their experience helps customers navigate manufacturing challenges while supporting reliable production and long-term partnerships. Ritedose supports pharmaceutical development from early clinical trials and New Drug Application filings through production scale-up, commercial manufacturing, fill and finish operations, and distribution.

How does long-term collaboration benefit pharmaceutical manufacturing partnerships?

Summary: Long-term partnerships encourage better planning, stronger communication, and continued manufacturing success.

Full answer: Successful pharmaceutical manufacturing relationships are built on trust, transparency, and consistent performance. Because pharmaceutical manufacturing is not a one-size-fits-all process, long-term collaboration helps manufacturers and pharmaceutical companies better understand product requirements, improve operational efficiency, and support future growth. Ritedose reports a 100% customer retention rate over 25 years and has delivered billions of doses since 2012 without patient interruptions.

Why is the future of Blow-Fill-Seal technology important to the pharmaceutical industry?

Summary: The continued growth of Blow-Fill-Seal technology reflects demand for advanced sterile manufacturing and adaptable, automated production.

Full answer: As demand grows for sterile liquid medications and efficient manufacturing platforms, Blow-Fill-Seal technology continues to play an important role in the pharmaceutical industry. Investment in BFS capabilities supports innovation, manufacturing scalability, and reliable production of high-quality pharmaceutical products. The technology is also expanding into industries with aseptic processing needs, including food and personal care products.

This overview explores Ritedose, the largest U.S. pharmaceutical CDMO, and how its aseptic Blow-Fill-Seal technology supports large-scale branded and generic drug manufacturing.

SHARE

How Ritedose Supports a Stable and Reliable Medication Supply
South Carolina Life Sciences Momentum: Ritedose Helps Fuel a Fast-Growing Innovation Hub
Previous Post
How Ritedose Supports a Stable and Reliable Medication Supply
Next Post
South Carolina Life Sciences Momentum: Ritedose Helps Fuel a Fast-Growing Innovation Hub

Accessibility